Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC)

Next Previous
Trial Profile

A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Tucidinostat (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors HUYA Bioscience International

Most Recent Events

  • 30 Jul 2026 Actual primary completion date changed from 1 Sep 2023 to 12 Dec 2023.
  • 08 Nov 2024 According to a HUYA Bioscience International media release, data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
  • 08 Nov 2024 Results from the final analysis of phase 2 study evaluating HBI-8000 in combination with nivolumab (anti-PD1 therapy), a novel combination for the treatment of advanced and metastatic melanoma presented in the HUYABIO Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top